Compugen appoints Michele Holcomb to board to accelerate clinical development and partnerships

Compugen appoints veteran biotech executive to strengthen board capacity

Board addition aims to accelerate clinical execution and partnerships

Compugen names Michele Holcomb, Ph.D., to its board as an independent director, positioning the Israeli clinical-stage cancer immunotherapy firm to sharpen its strategic and operational capabilities. The company highlights Holcomb’s more than three decades of experience in biotech, pharmaceuticals and healthcare services — including senior roles at Cardinal Health and Teva Pharmaceuticals — as directly relevant to advancing Compugen’s translational and partnering objectives. Compugen’s executive chair, Anat Cohen‑Dayag, says Holcomb’s background in strategy, business development and R&D operations will help convert the company’s pipeline opportunities into patient and commercial outcomes.

Management frames the appointment as part of a push to accelerate program development and external collaborations. Compugen is developing multiple potential first‑in‑class oncology programs discovered through its AI/ML computational platform, and the board addition is presented as a move to tighten program prioritization, licensing evaluation and integration of partnered assets. Holcomb’s prior responsibility for evaluating pipeline assets and overseeing global R&D operations at large pharmas is expected to inform decisions on clinical timing, cross‑functional execution and selection of strategic partners.

Holcomb says she joins a company that repeatedly generates and advances differentiated cancer programs and that Compugen’s combination of scientific innovation and disciplined partnering provides a compelling platform for sustained value creation. Her hands‑on experience with investments, acquisitions and portfolio optimization is likely to influence Compugen’s approach to deal structure, development sequencing and operational scale‑up as programs move through IND and early clinical milestones.

Compugen enters the year citing financial strength, two validating pharmaceutical partnerships and a differentiated computational discovery engine as foundations for advancing its pipeline. The company frames the board appointment as complementary to those strengths, aiming to shorten timelines from target identification to clinic while enhancing partner engagement.

Holcomb is noted as a scientist and executive who has led strategy, portfolio review and integration efforts across public and private boards. Compugen says her blend of scientific, strategic and commercial insight is expected to facilitate partnering and development execution across its oncology portfolio.